<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105701</url>
  </required_header>
  <id_info>
    <org_study_id>5172-068</org_study_id>
    <secondary_id>2014-000824-12</secondary_id>
    <nct_id>NCT02105701</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)</brief_title>
  <official_title>A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects Who Have Failed Prior Treatment With Pegylated Interferon and Ribavirin (P/R) With Chronic HCV GT1, GT4, and GT6 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir
      (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus
      (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated
      interferon and RBV. The primary study hypothesis is that in at least one of the study arms,
      the percentage of participants achieving sustained viral response 12 weeks after the end of
      all study treatment (SVR12) will be superior to 58%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12)</measure>
    <time_frame>12 weeks after the end of all study treatment (up to 28 weeks)</time_frame>
    <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AE)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Undetectable HCV RNA 24 Weeks After the End of All Treatment (SVR24)</measure>
    <time_frame>24 weeks after the end of all study treatment (up to 40 weeks)</time_frame>
    <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Grazoprevir + Elbasvir 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir + Elbasvir + RBV 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir + Elbasvir 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir + Elbasvir + RBV 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir + Elbasvir</intervention_name>
    <description>FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.</description>
    <arm_group_label>Grazoprevir + Elbasvir 12 weeks</arm_group_label>
    <arm_group_label>Grazoprevir + Elbasvir + RBV 12 weeks</arm_group_label>
    <arm_group_label>Grazoprevir + Elbasvir 16 weeks</arm_group_label>
    <arm_group_label>Grazoprevir + Elbasvir + RBV 16 weeks</arm_group_label>
    <other_name>MK-5172A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>200 mg capsule</description>
    <arm_group_label>Grazoprevir + Elbasvir + RBV 12 weeks</arm_group_label>
    <arm_group_label>Grazoprevir + Elbasvir + RBV 16 weeks</arm_group_label>
    <other_name>Rebetol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented chronic HCV GT1, GT4, or GT6 with no evidence of non-typable or mixed
             genotype infection (positive for anti-HCV antibody, HCV ribonucleic acid [RNA], or any
             of the listed GTs at least 6 months prior to screening must be confirmed by screening
             lab results)

          -  Cirrhosis defined as liver biopsy showing METAVIR F4; or Fibroscan showing result
             &gt;12.5 kilopascals (kPa); or FibroSure® (Fibrotest®) score of &gt;0.75 and an aspartate
             aminotransferase (AST):platelet ratio index (APRI) of &gt;2

          -  Absence of cirrhosis defined as liver biopsy showing absence of cirrhosis; or
             Fibroscan result of ≤ 12.5 kPa; or Fibrosure® (Fibrotest®) score of ≤ 0.48 and APRI ≤
             1

          -  Previous HCV treatment status of peginterferon/RBV Null responder; or
             peginterferon/RBV Partial responder; or peginterferon/RBV Treatment Relapse

          -  For human immunodeficiency virus (HIV) co-infected participants: documented HIV-1
             infection; currently naïve to treatment with any antiretroviral therapy (ART) and have
             no plans to initiate ART treatment while participating in this study; or be on HIV ART
             for at least 8 weeks prior to study entry (dual nucleoside reverse transcriptase
             inhibitor [NRTI] backbone of tenofovir or abacavir and either emtricitabine or
             lamivudine plus raltegravir (or dolutegravir or rilpivirine) (no changes in HIV
             regimen allowed within 4 weeks of randomization); cluster of differentiation 4 (CD4)+
             T-cell count &gt;200 cells/mm^3 at screening; documented undetectable plasma HIV-1 RNA at
             least 8 weeks prior to screening; participants not on ART, HIV RNA must be &lt;50,000
             copies/mL; must have at least one viable antiretroviral regimen alternative beyond
             their current regimen in the event of HIV virologic failure and the development of
             antiretroviral drug resistance

          -  Agree to use two acceptable methods of birth control from at least 2 weeks prior to
             Day 1 and continue until at least 6 months after last dose of study drug, or longer if
             dictated by local regulations; a male participant who is not (or whose partner is not)
             of reproductive potential is eligible without requiring the use of contraception

        Exclusion Criteria:

          -  Evidence of decompensated liver disease manifested by the presence of or history of
             ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other
             signs or symptoms of advanced liver disease

          -  For participants with cirrhosis, participants who are Child-Pugh Class B or C or who
             have a Pugh-Turcotte (CPT) score &gt;6, must be excluded

          -  Co-infected with hepatitis B virus

          -  Has had previous direct-acting antiviral treatment

          -  History of malignancy &lt;=5 years prior except for adequately treated basal cell or
             squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under
             evaluation for other active or suspected malignancy

          -  Has cirrhosis and liver imaging showing evidence of hepatocellular carcinoma (HCC) or
             is under evaluation for HCC

          -  Taking or plans to take any HIV therapy that includes a ritonavir-boosted or unboosted
             protease inhibitor, efavirenz or etravirine

          -  Currently participating or has participated in a study with an investigational
             compound within 30 days of signing informed consent and is not willing to refrain from
             participating in another such study during the course of this study

          -  Clinically-relevant drug or alcohol abuse within 12 months

          -  Pregnant, breast-feeding, or expecting to conceive or donate eggs or sperm from Day 1
             and continue until at least 6 months after last dose of study drug, or longer if
             dictated by local regulations; or is a male whose female partner(s) is/are pregnant

          -  History of organ transplant (including hematopoietic stem cell transplants) other than
             cornea and hair

          -  Poor venous access

          -  History of gastric surgery (e.g., stapling, bypass) or history of malabsorption
             disorders (e.g., celiac sprue disease)

          -  Hemoglobinopathy, including, but not limited to, thalassemia major

          -  Any medical condition requiring, or likely to require, chronic systemic
             corticosteroids, tumor necrosis factor (TNF) antagonists, or other immunosuppressant
             drugs during the course of the trial

          -  For participants with HIV, history of opportunistic infection in the preceding 6
             months

          -  For participants with HIV, use of HIV drugs other than a dual NRTI backbone of
             tenofovir or abacavir and either emtricitabine or lamivudine plus raltegravir (or
             dolutegravir or rilpivirine)

          -  Evidence or history of chronic hepatitis not caused by HCV, including but not limited
             to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune
             hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017 Jan;152(1):164-175.e4. doi: 10.1053/j.gastro.2016.09.045. Epub 2016 Oct 5.</citation>
    <PMID>27720838</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <results_first_submitted>February 3, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2016</results_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Grazoprevir + Elbasvir 12 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Grazoprevir + Elbasvir + RBV 12 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Grazoprevir + Elbasvir 16 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Grazoprevir + Elbasvir + RBV 16 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Grazoprevir + Elbasvir 12 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Grazoprevir + Elbasvir + RBV 12 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Grazoprevir + Elbasvir 16 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Grazoprevir + Elbasvir + RBV 16 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="105"/>
            <count group_id="B4" value="106"/>
            <count group_id="B5" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.71" spread="9.81"/>
                    <measurement group_id="B2" value="55.46" spread="8.26"/>
                    <measurement group_id="B3" value="54.91" spread="9.79"/>
                    <measurement group_id="B4" value="54.98" spread="9.61"/>
                    <measurement group_id="B5" value="55.27" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12)</title>
        <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>12 weeks after the end of all study treatment (up to 28 weeks)</time_frame>
        <population>The Full Analysis Set (FAS) population consists of all randomized subjects who receive at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir + Elbasvir 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir + Elbasvir + RBV 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir + Elbasvir 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir + Elbasvir + RBV 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12)</title>
          <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population consists of all randomized subjects who receive at least one dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="85.5" upper_limit="96.7"/>
                    <measurement group_id="O2" value="94.2" lower_limit="87.9" upper_limit="97.9"/>
                    <measurement group_id="O3" value="92.4" lower_limit="85.5" upper_limit="96.7"/>
                    <measurement group_id="O4" value="98.1" lower_limit="93.4" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR12 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR12 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR12 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR12 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events (AE)</title>
        <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The All Participants as Treated (APaT) population consists of all participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir + Elbasvir 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir + Elbasvir + RBV 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir + Elbasvir 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir + Elbasvir + RBV 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AE)</title>
          <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>The All Participants as Treated (APaT) population consists of all participants who received at least one dose of study treatment.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Study Treatment Due to an AE</title>
        <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>The All Participants as Treated (APaT) population consists of all participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir + Elbasvir 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir + Elbasvir + RBV 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir + Elbasvir 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir + Elbasvir + RBV 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Treatment Due to an AE</title>
          <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>The All Participants as Treated (APaT) population consists of all participants who received at least one dose of study treatment.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Undetectable HCV RNA 24 Weeks After the End of All Treatment (SVR24)</title>
        <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>24 weeks after the end of all study treatment (up to 40 weeks)</time_frame>
        <population>The Full Analysis Set (FAS) population consists of all randomized subjects who receive at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir + Elbasvir 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir + Elbasvir + RBV 12 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir + Elbasvir 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir + Elbasvir + RBV 16 Weeks</title>
            <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Undetectable HCV RNA 24 Weeks After the End of All Treatment (SVR24)</title>
          <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population consists of all randomized subjects who receive at least one dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="84.4" upper_limit="96.0"/>
                    <measurement group_id="O2" value="94.2" lower_limit="87.9" upper_limit="97.9"/>
                    <measurement group_id="O3" value="89.5" lower_limit="82.0" upper_limit="94.7"/>
                    <measurement group_id="O4" value="95.3" lower_limit="89.3" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR24 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR24 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR24 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that at least 1 treatment arm would have a SVR24 rate &gt;58%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>One-sided Exact Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 40.</time_frame>
      <desc>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>GZR/EBR 12 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>GZR/EBR + RBV 12 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>GZR/EBR 16 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.</description>
        </group>
        <group group_id="E4">
          <title>GZR/EBR + RBV for 16 Weeks</title>
          <description>Participants received grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Intestinal angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Splenic marginal zone lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="19" subjects_affected="17" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="104"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="105"/>
                <counts group_id="E4" events="33" subjects_affected="32" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="23" subjects_affected="14" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="105"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="105"/>
                <counts group_id="E4" events="22" subjects_affected="20" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

